Stopping Ozempic? New study reveals surprising weight regain results after GLP-1s

Study of ~8,000 adults who used semaglutide or tirzepatide for 3–12 months found average weight loss of 8.4% at discontinuation among patients treated for obesity and only a 0.5 percentage-point regain one year after stopping. An estimated 27% transitioned to other medications, 20% restarted the original drug, and 14% entered intensive lifestyle programs, suggesting continued care engagement may blunt the rapid rebound seen in randomized trials. Results come from a single large integrated health system in Ohio and Florida, limiting generalizability and potentially reflecting unmeasured concurrent interventions.

Analysis

Real-world patient pathways (switching, restarting, and formal lifestyle programs) turn a one-off pharmacologic response into a series of revenue and engagement events rather than a binary “on/off” outcome. Even modest persistence or cycling back onto therapy—if sustained across a large installed base—magnifies lifetime patient spend and raises customer acquisition ROI for incumbents, because the marginal cost of additional prescription months is mostly incremental manufacturing and distribution rather than repeat marketing.

This dynamic creates asymmetric winners across the ecosystem. Manufacturers and PBMs that can productize maintenance (auto‑refill, co-pay support, care navigation) capture recurring revenue and data that lock in formularies; ancillary service providers (telehealth/weight‑management platforms, specialty pharmacies, adherence/digital coaches) see higher ARPU and can cross‑sell metabolic monitoring. Conversely, firms exposed to one-time interventions (elective bariatric surgery providers, single‑use device vendors reliant on a high churn of new starts) face secular volume risk if clinical pathways prioritize chronic medical management over surgery.

Key catalysts and failure modes are timing-dependent: safety signals or rapid, broad payer denials would compress demand within weeks and reprice equities; by contrast, structural moves (oral incretin approvals, national formulary redesigns, or meaningful price concessions) play out over 6–36 months and reallocate margin pools across pharma, PBMs, and providers. High‑frequency indicators to watch are monthly script counts, prior‑authorization denial trends, specialty pharmacy reorder rates, and bariatric surgery volumes—these will telegraph whether the market is moving toward durable chronic therapy or episodic stop/start usage.

Key Decisions for Investors

• Long selective incretin franchise exposure via 9–12 month call spreads on NVO and LLY (buy 10–15% OTM call spreads). Size as a tactical bucket (1–2% notional each). Rationale: upside if real‑world persistence drives higher lifetime revenue; downside limited to premium. Target 2–3x premium on favorable adoption/coverage commentary; stop‑loss = full premium.
• Long telehealth/behavioral weight‑management providers (e.g., TDOC or WW) via 6–12 month calls or modest equity buys. Rationale: these businesses monetize patient retention and transition patients off/on drugs; expected re‑rating if payers embrace bundled chronic care. Risk: if payers cut access, options expire worthless—keep position size small (<=1.5% NAV).
• Buy UNH (or other large PBM/payer equities) on 6–12 month horizon; thesis: PBMs capture negotiating leverage and can monetize chronic therapy management fees. Reward: incremental revenue per member per month and reduced churn; risk: regulatory/political headline risk that could compress P/E multiples—trim on >15% pop.
• Pair trade: long leading drug franchises (LLY/NVO call spreads) vs underweight/short elective surgery exposure (ISRG) over 12–24 months. Rationale: continued medical management reduces elective surgical volumes; hedges broad health‑care beta. Size the short to be smaller than the long to control event‑risk from surgical backlog rebounds; target asymmetry 1.5:1.